<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer &#187; product rights</title>
	<atom:link href="http://akampioneer.com/tag/product-rights/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Mon, 14 May 2012 08:00:40 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.1</generator>
		<item>
		<title>Company News: MediGene Sells Full European Rights for Eligard® to Astellas for EUR 25 Million and Ongoing Royalties</title>
		<link>http://akampioneer.com/company-news/company-news-medigene-sells-full-european-rights-for-eligard%c2%ae-to-astellas-for-eur-25-million-and-ongoing-royalties.html</link>
		<comments>http://akampioneer.com/company-news/company-news-medigene-sells-full-european-rights-for-eligard%c2%ae-to-astellas-for-eur-25-million-and-ongoing-royalties.html#comments</comments>
		<pubDate>Tue, 20 Jul 2010 13:16:44 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Astellas Pharma Europe]]></category>
		<category><![CDATA[Eligard]]></category>
		<category><![CDATA[MediGene]]></category>
		<category><![CDATA[product rights]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=455</guid>
		<description><![CDATA[MediGene AG (Frankfurt, Prime Standard, MDG, TecDAX) has announced the sale of full European marketing and distribution rights to Eligard® (leuprolide acetate, for the treatment of hormone-dependent prostate cancer) to Astellas Pharma Europe Ltd. (London, &#8220;Astellas&#8221;), previously MediGene&#8217;s European marketing partner for Eligard®. Astellas will make one-off payments totalling EUR 25 million, while MediGene remains [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-medigene-sells-full-european-rights-for-eligard%c2%ae-to-astellas-for-eur-25-million-and-ongoing-royalties.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

